2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive...

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Hematology

Background:

• The Janus kinase 2 (JAK2)/signal transducer and activator of transcription (STAT) pathway is crucial for blood cell formation (hematopoiesis).
• The JAK2 V617F mutation is frequently found in patients with myeloproliferative neoplasms (MPNs), driving significant research into JAK2 inhibitors.
• Existing JAK2 inhibitors face challenges related to potential drug-induced toxicity.

Purpose of the Study:

• To design and synthesize novel potent inhibitors of the JAK2/STAT pathway.
• To explore a new chemical scaffold, the 2,7-pyrrolotriazine core, for JAK2 inhibition.
• To investigate and minimize potential glutathione adduct formation, a marker of drug-induced toxicity.

Main Methods:

• Synthesis of a novel series of 2,7-pyrrolotriazine compounds.
• Evaluation of JAK2 inhibitory potency for the synthesized compounds.
• Assessment of glutathione adduct formation for the lead compounds and their analogs.
• Structure-activity relationship analysis focusing on substituents at the C2 position.

Main Results:

• A novel series of potent JAK2 inhibitors based on the 2,7-pyrrolotriazine core was successfully synthesized.
• Compounds demonstrated significant JAK2 inhibitory activity.
• Modification of the aniline substituent at the C2 position markedly decreased glutathione adduct formation.
• The C2-modified compounds represent a promising direction for developing safer JAK2 inhibitors.

Conclusions:

• The 2,7-pyrrolotriazine core represents a viable scaffold for developing potent JAK2 inhibitors.
• Strategic modification of the C2 aniline substituent can effectively reduce the potential for glutathione adduct formation, thereby mitigating drug-induced toxicity.
• These findings pave the way for the development of safer and more effective therapies for MPNs and other conditions driven by JAK2 signaling.